PTC Therapeutics Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category
- New category targets programs that support the transition from adolescence to adulthood -
- Proposal submissions for 2021 STRIVE Awards are due March 15, 2021 -
News provided by
Share this article
Share this article
SOUTH PLAINFIELD, N.J., Jan. 14, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the seventh annual STRIVE Awards program for Duchenne muscular dystrophy. The Awards provide a grant to patient advocacy organizations around the world who are committed to developing innovative and sustaining programs that help address the unmet needs of the rare disease community. This year, a new entry category dedicated to supporting programs that focus on the transition of those living with Duchenne from adolescence to adulthood has been introduced.
email article
Rapper and entrepreneur Dr. Dre, 55, was hospitalized earlier this month after suffering symptoms related to a brain aneurysm. He was taken by ambulance to Cedar Sinai hospital in Los Angeles where he was admitted to the intensive care unit. The next day, he was reported to be lucid and shared an update on Instagram: Thanks to my family, friends and fans for their interest and well wishes. I m doing great and getting excellent care from my medical team. I will be out of the hospital and back home soon. Shout out to all the great medical professionals at Cedars. One Love!!
Stroke survivors who had ceased to benefit from conventional rehabilitation gained clinically significant arm movement and control by using an external robotic device powered by their own brains, according to a study published in
Most patients retained the benefits for at least 2 months after the therapy sessions ended, suggesting the potential for long-lasting gains, Jose Luis Contreras-Vidal, director of the Non-Invasive Brain Machine Interface Systems Laboratory at the University of Houston, shares in a media release from the University of Houston.
Move on Demand
The trial involved training stroke survivors with limited movement in one arm to use a brain-machine interface (BMI), a computer program that captures brain activity to determine the subject’s intentions and then triggers an exoskeleton, or robotic device affixed to the affected arm, to move in response to those intentions. The device wouldn’t move if intention wasn’t detected, ensuring subjects remained engage
Blood Test May Help Diagnose Alzheimer s Disease, Scientists Say
Doctors May Soon Be Able To Diagnose Patients With Two Common Forms of Dementia
By Newsweek AMPLIFY On 1/12/21 at 11:20 PM EST
Around 50 million people live with Alzheimer s, a degenerative brain disease that accounts for more than half of global dementia cases. Alzheimer s disease is an age-related brain disorder that develops over many years. However, certain aggravating factors damage the brain cells much faster so even a person who is as young as 30 years old can already experience the early signs of Alzheimer s.
Memory loss, forgetting the subject of conversation midway, and irrational mood changes are just some of the early symptoms of Alzheimer s disease. These symptoms can easily be mistaken as every day, stress-driven occurrences. Without regular extensive checkups, a person is often diagnosed with Alzheimer s when symptoms have already worsened.
Stroke survivors who had ceased to benefit from conventional rehabilitation gained clinically significant arm movement and control by using an external robotic device powered by the patients' own brains.